Viron Therapeutics wins Prix Galien award for VT-111

London ON-based Viron Therapeutics Inc has won the prestigious Prix Galien Canada Award for its work developing a class of medicines targeting inflammatory-based disorders. The award was made November 16 and recognizes Viron’s development of VT-111, a class of virally-derived biologics that could revolutionize the way cardiovascular disease is currently treated. VT-111 is currently in Phase II clinical trials for acute coronary syndromes and late preclinical studies for transplant vasculopathy. Viron is a spin off of the Robarts Research Institute and was founded by Dr Grant McFadden, the company’s chief scientific officer and Dr Alexandra Lucas, its chief clinical officer….